Business » Industry

Updated: November 24, 2013 00:34 IST

Pfizer, Wyeth to merge into single brand

  • PTI
Comment (1)   ·   print   ·   T  T  
Aijaz Tobaccowalla
The Hindu
Aijaz Tobaccowalla

The share swap ratio is fixed at 7:10

Drug majors Pfizer and Wyeth, on Saturday, said they would merge their India operations in a share-swap and operate under a single brand, a move that would give the combined entity increased therapeutic presence and a de-risked business profile.

The operations would be unified under the ‘Pfizer brand’

The boards of Pfizer India and Wyeth India approved a swap ratio, which would give Wyeth shareholders seven Pfizer shares for every ten they hold.

Interim dividend

The companies have also announced separate interim dividend payouts in which Pfizer will give Rs.360 a share, while Wyeth will give Rs.145 a share.

Wyeth will cease to exist as a separate legal and brand entity in the country. For the year ended March, 2013, Wyeth reported total revenues of Rs.714 crore and profit of Rs.130 crore. On the other hand, Pfizer India clocked revenues of Rs.1,156 crore and a bottom-line of Rs.503 crore.

“The boards of Pfizer India and Wyeth India have given their approval to merge the two companies, which will create a single Pfizer brand...the combined entity would have increased therapeutic presence and a de-risked business profile,” Pfizer India and Wyeth India Managing Director Aijaz Tobaccowalla told reporters here.

He said the merger process would take nine months to complete as it involved a string of approvals.

The U.S. drug giant Pfizer Inc had acquired its homegrown rival Wyeth for $68 billion in 2009 and Wyeth became a subsidiary of Pfizer Inc in India.

Wider market access

“We will have increased product base with wider access to market. This merger will also improve our market share and strengthen the competitive position,” Mr. Tobaccowalla said, adding segments such as women’s health, vaccines, respiratory, CNS, anti-infective would be on high focus for the company.

Pfizer will issue around 15.9 million new shares to Wyeth shareholders for this merger. The recommended swap ratio has been reviewed by merchant bankers, who have issued separate fairness opinions to the respective board of directors, the two companies said.

“Implied pro-forma shareholding of Pfizer Inc, post-merger will be 63.9 per cent,” the company said.

Strong financial profile

Talking on Pfizer India post-merger, Mr. Tobaccowalla said the combined entity would have a strong financial profile with improved market share.

Pfizer India is not a big player enjoying only 1.9 per cent market share. Its market value stands at Rs.1,281 crore, while Wyeth is valued at Rs.832 crore as per Friday’s closing price.

More In: Industry | Business

This part which is business strategy is fine and the guy should
remember that it is not very important to satisfy the shareholders,
but the most important and fundamental issue is to satisfy the Doctors
who are end users, patients who use them under the care of Primary
Care and other specialty groups.
You will be able to survive the competition till that day you prove to
the consumer that the products you are trying to sell is
therapeutically superior over the existing ones and the cost is within
the reach. The cost of the product assume secondary importance when
you prove the product delivers its promise to cure, relieve or
minimize the sickness so as to rehabilitate the patient. My experience
then the price becomes secondary, as the patient look at how soon one
will be able to resume his work.

from:  sini
Posted on: Nov 23, 2013 at 21:32 IST
This article is closed for comments.
Please Email the Editor

Commodity prices

Take a look at the prices of various commodities in Chennai here»





Recent Article in Industry

File photo shows a Vedanta Resources-owned alumina refinery in Orissa.

Vedanta India to acquire up to 5.33% stake in Cairn India

After the acquisition of the shares, Vedanta India’s stake in Cairn India will grow from 18.73 per cent to 24.06 per cent. »